GPP
ATRA icon

Great Point Partners’s Atara Biotherapeutics ATRA Stock Holding History

Great Point Partners’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,800
Closed -$1.15M – 37
2019
Q4 		$1.15M Sell
2,800
-17,200
-86% -$5.93M 0.1% 36
2019
Q3 		$7.06M Buy
+20,000
New +$7.46M 0.65% 34

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Great Point Partners's ATRA Position: Q1 2020 in Review

Great Point Partners sold out of Atara Biotherapeutics (ATRA) in Q1 2020, closing a stake of 2,800 shares — an estimated $1.15M sold.

Great Point Partners first reported a position in ATRA in Q3 2019 and held it in 2 quarters. The position peaked at $7.06M in Q3 2019. 111 funds tracked by Wall St. Rank hold ATRA as of Q1 2020.

  • Great Point Partners reported no remaining Atara Biotherapeutics position as of Q1 2020 after selling out during the quarter.
  • Great Point Partners sold 2,800 Atara Biotherapeutics shares in Q1 2020, an estimated $1.15M.
  • Great Point Partners first reported a position in Atara Biotherapeutics in Q3 2019 and held it in 2 quarters.
  • Great Point Partners's Atara Biotherapeutics position peaked at $7.06M in Q3 2019.
  • 111 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2020.

Based on Great Point Partners's 13F filing for Q1 2020, filed 15 May 2020.